IQVIA Holdings (IQV) 10-K Summary — Year Ended Dec 31, 2024
IQVIA provides clinical research, commercial insights, and healthcare intelligence to life sciences and healthcare clients. The filing reports an increase in revenue and positive operating cash flow for the latest period.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
IQVIA provides clinical research, commercial insights, and healthcare intelligence to life sciences and healthcare clients. The filing reports an increase in revenue and positive operating cash flow for the latest period.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$15.4B
Revenue reported for the fiscal year.
Operating income
$2.2B
Income from operations reported for the year.
Net income
$1.4B
Net income reported for the year.
Operating cash flow
$2.7B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $13.9B | n/a |
| Dec 31, 2022 | $14.4B | +3.9% |
| Dec 31, 2023 | $15B | +4.0% |
| Dec 31, 2024 | $15.4B | +2.8% |
Business overview
IQVIA is a global provider of clinical research services, commercial insights, and healthcare intelligence, serving the life sciences and healthcare industries. Its solutions are powered by IQVIA Connected Intelligence, combining health data, healthcare-grade AI, advanced analytics, and domain expertise. The company employs approximately eighty-eight thousand people across over one hundred countries, focusing on accelerating the development and commercialization of medical treatments while protecting patient privacy.
Financial performance
Revenue for the year ended December thirty-first, two thousand twenty-four grew compared to the prior year, continuing a multi-year upward trend. Operating income and net income were both positive, and cash from operations was strong. The filing does not provide further segment-level or profitability trend details beyond these figures.
Material risks
The filing notes that forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially. No specific material risks are elaborated in the provided risk factors section text beyond the general caution regarding forward-looking statements. The company also acknowledges commitments regarding responsible use of artificial intelligence and regulatory compliance.
Liquidity and capital
The company has a long-standing share repurchase program, with the board authorizing additional repurchase capacity in early two thousand twenty-five. The filing states that repurchases are discretionary and depend on market price, corporate needs, and market conditions.
What to watch
Revenue growth trajectory and the trend in operating cash flow generation will indicate whether the company's core service demand remains stable.